Datailai Cetuximab N01 Injection

1. Indications and Usage
Metastatic Colorectal Cancer (mCRC):
First-line: In combination with mFOLFOX or FOLFIRI for RAS wild-type mCRC.
Second-line: Monotherapy with irinotecan for RAS wild-type mCRC after irinotecan-based therapy failure.
Head and Neck Cancer:
In combination with platinum-based chemotherapy and fluorouracil for first-line treatment of recurrent and/or metastatic disease.
In combination with radiotherapy for locally advanced disease.
Genetic Requirement: Use is strictly restricted to patients confirmed to be RAS wild-type via validated diagnostic testing.
2. Dosage and Administration
Route of Administration: Intravenous infusion ONLY.
Standard Dosage: Initial dose of 400 mg/m² over 120 minutes; subsequent weekly doses of 250 mg/m² over 60 minutes.
Alternative Dosage: An alternative regimen of 500 mg/m² over 120 minutes every 2 weeks may be used.
Critical Administration Instructions:
Pre-medication: Premedication with an H1 receptor antagonist and corticosteroids is required prior to each infusion.
Preparation: No dilution is required. Use a separate infusion line and flush with 0.9% Sodium Chloride Injection after completion.
3. Mechanism of Action
EGFR Binding: Cetuximab N01 is a recombinant antibody that binds with high affinity to the extracellular domain of EGFR.
Signal Inhibition: It competitively inhibits ligand binding (e.g., EGF, TNF-α), blocking downstream signaling pathways responsible for cell proliferation and survival.
ADCC: It can mediate antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing EGFR.
4. Safety and Warnings
Hypersensitivity: Severe and fatal infusion-related reactions can occur, particularly in patients allergic to red meat or stinging insects (anti-α-gal antibodies).
Cardiopulmonary Arrest: Fatal cardiopulmonary arrests have been reported, particularly when combined with platinum-based chemotherapy and fluorouracil in head and neck cancer patients.
Dermatologic Toxicity: Acneiform rash is very common (≥80%); about 15% are severe and may lead to skin necrosis or secondary infections.
Hypomagnesemia: Very common electrolyte disturbance; serum magnesium and other electrolytes must be monitored regularly.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Skin reactions (acneiform rash, pruritus, dry skin), hypomagnesemia, infusion-related reactions, diarrhea, nausea, vomiting, fatigue, and elevated liver enzymes (ALT, AST).
Clinical Research Highlights: The phase III EMR 62202-006 trial demonstrated that Cetuximab N01 combined with mFOLFOX6 is clinically non-inferior to reference cetuximab in terms of objective response rate, with comparable safety and tolerability profiles.
6. Drug Interactions
Chemotherapy:
Combined with irinotecan: May increase severity of diarrhea and neutropenia.
Combined with 5-fluorouracil: Increases risk of myocardial ischemia and hand-foot syndrome.
Combined with platinum agents: Increases risk of severe leukopenia or neutropenia.
Radiotherapy: Combined use in head and neck cancer increases the risk of mucositis and radiation dermatitis.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Cetuximab N01.
Appearance: Colorless to pale yellow clear liquid.
Packaging: Available in 100 mg/50 mL vials.
Storage: Store at 2°C to 8°C protected from light. Do not freeze or shake.